Dry Weight Reduction Intervention Via Extra Ultrafiltration
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
Most patients who receive hemodialysis treatments have excess fluid in their body that has slowly built up over the course of kidney disease. This extra fluid is the main cause of high blood pressure in dialysis and leads to stress on the heart and lungs.that causes debilitating symptoms and frequent hospitalizations. This trial will test whether a focused program of 4 or 8 weeks of extra ultrafiltration treatments can remove most of this extra fluid. We believe that getting rid of large amounts of extra fluid will result in sustained improvements in blood pressure and symptoms. Ultrafiltration is a gentler type of dialysis that removes fluid but does not clean the blood.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * Receiving thrice weekly in-center hemodialysis treatments for end stage kidney disease for at least four weeks and clinical suspicion of volume excess based on either: 1. Persistent hypertension defined by three consecutive pre-dialysis systolic blood pressures ≥140 mmHg or three consecutive pre-dialysis systolic blood pressures 130-140 mmHg plus use of at least two anti-hypertensive medications that can be tapered. OR 2. Symptoms of congestion defined by a 12-item Kidney Modified Kansas City Cardiomyopathy Questionnaire (KM-KCCQ) score \<75. Exclusion Criteria: * Age \<18 years * Receiving hemodialysis treatments for acute kidney injury * Receiving hemodialysis treatments for less than four weeks * Planned switch to peritoneal or home dialysis within next three months * Current or planned incremental hemodialysis (less than 3 treatments per week) * Current or planned intensive hemodialysis (four or more treatments per week) * Scheduled kidney transplantation * Major cardiovascular or bleeding event within previous 90 days * Receiving chemotherapy or radiation treatment for cancer * History of cirrhosis with ascites * Inability to complete 24-hour ambulatory blood pressure measurement * Wheelchair dependance or other inability to complete six-minute walk test * Pre-dialysis systolic blood pressure \<100 mmHg * Scheduled use of midodrine with hemodialysis treatments * History of non-adherence with dialysis treatments * Pregnancy * Institutionalized * Current or pending enrollment in hospice care * Inappropriate for enrollment based on investigator or nephrologist discretion
Study sites (1)
WA
- Northwest Kidney Centers · Seattle, WA 98112Luisa Rios-Avila · Study contact · 2062589325 · lrios1@uw.eduMore trials in Seattle